Immunotherapy Toxicity Management in NSCLC – OncLive
|
Immunotherapy Toxicity Management in NSCLC
OncLive Everett Vokes, MD: Briefly, Roy, can you comment on toxicities with checkpoint inhibitors? What are toxicities community oncologists should know? Roy Herbst, MD, PhD: Right. And that's the reason why we really want to make sure we have some efficacy. |
